Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-generation antihistamines: the OTC debate.

C S Sampey1, S L Follin

  • 1Rose Medical Center, Denver, CO 80220, USA. sampey1@msn.com

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|May 25, 2001
PubMed
Summary

Second-generation antihistamines (SGAs) demonstrate favorable safety profiles, meeting criteria for over-the-counter (OTC) availability. Consumers can safely self-treat allergic rhinitis with these newer, less sedating options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancement of a pharmacy consultation program on a transitional care unit.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Acute pain management: operative or medical procedures and trauma.

The Annals of pharmacotherapy·1997
Same author

Falsely elevated serum vancomycin concentrations in hemodialysis patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·1996
Same author

Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone.

Journal of clinical pharmacology·1995

Area of Science:

  • Pharmacology
  • Drug Safety
  • Regulatory Science

Background:

  • First-generation antihistamines (FGAs) are widely used OTC for allergic rhinitis but pose risks.
  • FGAs are associated with central nervous system (CNS) adverse effects, increasing accident risks and impacting children's learning.
  • Second-generation antihistamines (SGAs) offer improved safety profiles with fewer CNS effects.

Purpose of the Study:

  • To evaluate the safety profiles of second-generation antihistamines (SGAs).
  • To determine if SGAs meet Food and Drug Administration (FDA) criteria for over-the-counter (OTC) status.

Main Methods:

  • A comprehensive MEDLINE literature search was conducted.
  • Articles published between 1970 and 2000 were reviewed.
  • Safety data and FDA regulatory criteria were analyzed.

Main Results:

  • SGAs exhibit significantly fewer CNS adverse effects compared to FGAs.
  • SGAs do not appear to impair learning in children or cause significant drug interactions.
  • Several countries have already approved SGAs for OTC use.

Conclusions:

  • The established safety and efficacy of SGAs support their switch to OTC status.
  • Consumers should have access to SGAs for self-treatment of mild allergic rhinitis.
  • Regulatory bodies should consider SGAs for OTC availability based on safety data.

Related Experiment Videos